| Mr Cameron Michael Griffith, PT | |
|
5757 Whitmore Lake, Suite 900, Brighton, MI 48116-1956 | |
| (810) 220-5793 | |
| (810) 220-5805 |
| Full Name | Mr Cameron Michael Griffith |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 29 Years |
| Location | 5757 Whitmore Lake, Brighton, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427129659 | NPI | - | NPPES |
| 700C810410 | Other | MI | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 5501006866 (Michigan) | Secondary |
| 225100000X | Physical Therapist | 5501006866 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Plymouth Physical Therapy Specialists Limited Partnership | 3870488521 | 66 |
| Carolina Physical Therapy And Sports Medicine Limited Partnership | 7517236557 | 34 |
News Archive
K2M Group Holdings, Inc., a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine technologies, techniques and minimally invasive procedures, today announced the U.S. commercial launch of the MESA 2 Deformity Spinal System, the Company's next-generation pedicle screw system designed to address the most complex spinal pathologies.
More than 10 million Americans undergo surgical tooth extractions every year, and the procedure invariably involves some loss of bone from the tooth socket. This bone loss is problematic for dentists because it can compromise both the functional and esthetic outcomes of treatment involving dentures and bridges. Significant losses of bone also make it difficult for surgeons to properly fit dental implants to the ridge of the jawbone without requiring additional surgical procedures.
Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.
Protherics PLC today announced the initiation of a phase 2a proof-of-concept study of Prolarix, a targeted prodrug chemotherapy being developed for the treaent of primary liver cancer (hepatocellular carcinoma or "HCC"). This follows promising data from a phase 1 study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 June 2008.
› Verified 8 days ago
| Entity Name | Plymouth Physical Therapy Specialists Limited Partnership |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1174626329 PECOS PAC ID: 3870488521 Enrollment ID: O20070115000101 |
News Archive
K2M Group Holdings, Inc., a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine technologies, techniques and minimally invasive procedures, today announced the U.S. commercial launch of the MESA 2 Deformity Spinal System, the Company's next-generation pedicle screw system designed to address the most complex spinal pathologies.
More than 10 million Americans undergo surgical tooth extractions every year, and the procedure invariably involves some loss of bone from the tooth socket. This bone loss is problematic for dentists because it can compromise both the functional and esthetic outcomes of treatment involving dentures and bridges. Significant losses of bone also make it difficult for surgeons to properly fit dental implants to the ridge of the jawbone without requiring additional surgical procedures.
Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.
Protherics PLC today announced the initiation of a phase 2a proof-of-concept study of Prolarix, a targeted prodrug chemotherapy being developed for the treaent of primary liver cancer (hepatocellular carcinoma or "HCC"). This follows promising data from a phase 1 study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 June 2008.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Cameron Michael Griffith, PT 9368 N Lilley Rd, Plymouth, MI 48170-4610 Ph: (734) 416-3900 | Mr Cameron Michael Griffith, PT 5757 Whitmore Lake, Suite 900, Brighton, MI 48116-1956 Ph: (810) 220-5793 |
News Archive
K2M Group Holdings, Inc., a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine technologies, techniques and minimally invasive procedures, today announced the U.S. commercial launch of the MESA 2 Deformity Spinal System, the Company's next-generation pedicle screw system designed to address the most complex spinal pathologies.
More than 10 million Americans undergo surgical tooth extractions every year, and the procedure invariably involves some loss of bone from the tooth socket. This bone loss is problematic for dentists because it can compromise both the functional and esthetic outcomes of treatment involving dentures and bridges. Significant losses of bone also make it difficult for surgeons to properly fit dental implants to the ridge of the jawbone without requiring additional surgical procedures.
Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.
Protherics PLC today announced the initiation of a phase 2a proof-of-concept study of Prolarix, a targeted prodrug chemotherapy being developed for the treaent of primary liver cancer (hepatocellular carcinoma or "HCC"). This follows promising data from a phase 1 study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 June 2008.
› Verified 8 days ago